Tikva Allocell secured an $8 million Series A to advance TAVST-01, an engineered allogeneic cell therapy program aimed at adult and pediatric patients with solid tumors. The funding supports preclinical work and program progression toward clinical readiness. The company’s positioning centers on scalable, off-the-shelf cell therapy engineering rather than individualized cell manufacture. The round also signals continued investor focus on solid tumor cell-therapy approaches that promise broader access if manufacturing and safety can be maintained at scale. For the field, the new capital contributes to an expanding pipeline of allogeneic platforms trying to address the manufacturing and timing constraints that have limited cell therapy penetration in solid tumors.